Dissolution testing of oral modified-release dosage forms

被引:59
|
作者
Garbacz, Grzegorz [1 ]
Klein, Sandra [1 ]
机构
[1] Ernst Moritz Arndt Univ Greifswald, Inst Pharm, D-17489 Greifswald, Germany
关键词
biorelevant dissolution; gastrointestinal stress; gastrointestinal transit; modified-release; oral drug delivery; GASTROINTESTINAL PH PROFILES; IN-VIVO PERFORMANCE; INFLAMMATORY-BOWEL-DISEASE; DYNAMIC GASTRIC MODEL; DRUG-DELIVERY SYSTEM; BIORELEVANT DISSOLUTION; GAMMA-SCINTIGRAPHY; INTRALUMINAL PH; VITRO EVALUATION; HEALTHY-SUBJECTS;
D O I
10.1111/j.2042-7158.2012.01477.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives The in-vivo performance of oral modified-release dosage forms is determined by the interplay of various physiological- and dosage-form-derived parameters. Thus it is often a challenge to predict the in-vivo drug-release behaviour from modified-release dosage forms based solely on in-vitro release rates. Key findings For a long time the most common procedure to obtain in-vitro/in-vivo correlations for modified-release formulations was to apply test conditions typically used for quality control on a retrospective basis. Such so-called compendial approaches are typically not biorelevant with respect to volumes, composition and physicochemical properties of the test media and also do not take into consideration the mechanical and hydrodynamic forces that may influence dosage-form behaviour during passage through the gastrointestinal tract. Summary This review provides an overview of physiological conditions relevant to in-vivo drug release and of dissolution models which, based on current scientific findings on human gastrointestinal physiology, have been developed to enable a better prediction of the in-vivo performance of oral MR dosage forms.
引用
收藏
页码:944 / 968
页数:25
相关论文
共 50 条
  • [21] In vitro dissolution of oral modified-release tablets and capsules in ethanolic media
    Smith, Anjanette P.
    Moore, Terry W.
    Westenberger, Benjamin J.
    Doub, William H.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 398 (1-2) : 93 - 96
  • [22] ORAL MODIFIED RELEASE DOSAGE FORMS - QUO VADIS
    Baumgartner, S.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 44 : 26 - 27
  • [23] NATURAL POLYMERS FOR ORAL MODIFIED RELEASE DOSAGE FORMS
    Pavli, M.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 44 : 27 - 28
  • [24] BIOPHARMACEUTICAL ASPECTS OF ORAL MODIFIED RELEASE DOSAGE FORMS
    Bogataj, M.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 44 : 30 - 31
  • [25] BIOPHARMACEUTICAL ASSESSMENT OF MODIFIED RELEASE ORAL DOSAGE FORMS
    MOLLER, H
    PHARMAZEUTISCHE INDUSTRIE, 1986, 48 (05): : 514 - 519
  • [27] Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form
    Jantratid, Ekarat
    De Maio, Vincenzo
    Ronda, Ernanuela
    Mattavelli, Valentina
    Vertzoni, Maria
    Dressman, Jennifer B.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 37 (3-4) : 434 - 441
  • [28] REPORT OF THE WORKSHOP ON - INVITRO AND INVIVO TESTING AND CORRELATION FOR ORAL CONTROLLED MODIFIED RELEASE DOSAGE FORMS
    SKELLY, JP
    AMIDON, GL
    BARR, WH
    BENET, LZ
    CARTER, JE
    ROBINSON, JR
    SHAH, VP
    YACOBI, A
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 63 (02) : 83 - 93
  • [29] Dissolution testing and metrological measurement of quality for solid oral dosage forms
    Manning, Ronald G.
    Wahab, Samir Z.
    Brown, William E.
    Hauck, Walter W.
    Schuber, Stefan
    Williams, Roger L.
    Pharmaceutical Technology, 2007, 31 (05) : 68 - 74
  • [30] Gastrointestinal release behaviour of modified-release drug products: Dynamic dissolution testing of mesalazine formulations
    Goyanes, Alvaro
    Hatton, Grace B.
    Merchant, Hamid A.
    Basit, Abdul W.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 484 (1-2) : 103 - 108